MorphoSys AG (ETR:MOR) received a €68.00 ($80.95) price target from analysts at Berenberg Bank in a report issued on Tuesday. The firm currently has a “buy” rating on the stock.

MOR has been the topic of several other reports. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of MorphoSys AG in a report on Monday, July 17th. Goldman Sachs Group, Inc. (The) set a €55.00 ($65.48) target price on shares of MorphoSys AG and gave the stock a “neutral” rating in a report on Monday, July 17th. Commerzbank Ag set a €76.00 ($90.48) target price on shares of MorphoSys AG and gave the stock a “buy” rating in a report on Wednesday, September 6th. Deutsche Bank AG set a €90.00 ($107.14) target price on shares of MorphoSys AG and gave the stock a “buy” rating in a report on Tuesday, August 1st. Finally, Oddo Bhf set a €76.00 ($90.48) target price on shares of MorphoSys AG and gave the stock a “buy” rating in a report on Thursday, September 7th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. MorphoSys AG currently has a consensus rating of “Buy” and a consensus target price of €70.38 ($83.78).

MorphoSys AG (ETR MOR) traded up 2.036% during mid-day trading on Tuesday, hitting €70.869. 4,417 shares of the stock traded hands. MorphoSys AG has a one year low of €35.72 and a one year high of €71.91. The stock’s market capitalization is €2.05 billion. The company has a 50 day moving average price of €60.74 and a 200-day moving average price of €59.75.

TRADEMARK VIOLATION WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/24/berenberg-bank-analysts-give-morphosys-ag-mor-a-68-00-price-target.html.

MorphoSys AG Company Profile

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Analyst Recommendations for MorphoSys AG (ETR:MOR)

Receive News & Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related companies with MarketBeat.com's FREE daily email newsletter.